These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10750184)

  • 1. A needed technical fix?
    Robertson WO
    Vet Hum Toxicol; 2000 Apr; 42(2):118-9. PubMed ID: 10750184
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 3. Imprint coding on solid medication forms: problems in interpretation.
    Smolinske SC; Robertson WO
    Vet Hum Toxicol; 1992 Apr; 34(2):170-2. PubMed ID: 1509684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 5. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 6. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 7. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 8. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 9. Overdosage and-or poisoning--the information gap.
    Ellenhorn MJ
    J Clin Pharmacol; 1973; 13(5):181-9. PubMed ID: 4488653
    [No Abstract]   [Full Text] [Related]  

  • 10. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New classification of drugs.
    J Fla Med Assoc; 1972 Jan; 59(1):37. PubMed ID: 5058956
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety-related drug labeling changes approved by FDA.
    White GG
    J Toxicol Clin Toxicol; 1998; 36(3):265-7. PubMed ID: 9678979
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of orphan products.
    FDA Drug Bull; 1983 Apr; 13(1):2-4. PubMed ID: 6852406
    [No Abstract]   [Full Text] [Related]  

  • 14. Black box warnings-implications in practice.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(6):402-9. PubMed ID: 19064138
    [No Abstract]   [Full Text] [Related]  

  • 15. Ophthalmic drug products for over-the-counter human use; final monograph; technical amendment. Final rule; technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Feb; 68(33):7919-21. PubMed ID: 12593411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National drug policy in Nigeria. Interview by Daphne A. Fresle.
    Kuti OR
    J Public Health Policy; 1992; 13(3):367-73. PubMed ID: 1401053
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceutical analysis: key to drug quality and control.
    Florey KG; Brewer GA
    Am Pharm; 1981 Aug; NS21(8):30-5. PubMed ID: 7270421
    [No Abstract]   [Full Text] [Related]  

  • 18. The Bureau of Drug Abuse Control: a review of the first two years.
    Gunn JW
    J Forensic Sci; 1968 Jul; 13(3):302-17. PubMed ID: 5757498
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug imprinting ('unit labeling')--an update and a plea!
    Chi B; Serafin D; Robertson WO
    Vet Hum Toxicol; 2003 Feb; 45(1):1-2. PubMed ID: 12583685
    [No Abstract]   [Full Text] [Related]  

  • 20. An overview of current programs on drug development and regulation for small ruminants--pharmaceutical industry perspective.
    Terry M
    Vet Hum Toxicol; 1993; 35 Suppl 2():12-3. PubMed ID: 8236759
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.